StoxAlkem Laboratories vs Abbott India: share price & financials comparison
NSE: ALKEM vs ABBOTINDIA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Alkem Laboratories vs Abbott India at a glance
Alkem Laboratories (ALKEM) has a market capitalisation of ₹63,326 Cr, against ₹55,983 Cr for Abbott India (ABBOTINDIA). Over the past year Alkem Laboratories has returned -4.3%, compared with -11.3% for Abbott India. On valuation, Alkem Laboratories trades at a lower P/E of 29.4 versus 34.7. Alkem Laboratories comes out ahead on valuation and momentum. Abbott India comes out ahead on profitability and technicals. Across the scored metrics below, Alkem Laboratories leads on 6 and Abbott India on 6. On StoxGud's 10-point checklist, Alkem Laboratories scores 6/10 and Abbott India scores 5/10.
| Metric | Alkem Laboratories | Abbott India |
|---|---|---|
| Size | ||
| Market cap | ₹63,326 Cr | ₹55,983 Cr |
| Revenue (latest FY) | ₹14,712 Cr | — |
| Net profit (latest FY) | ₹2,302 Cr | — |
| Valuation | ||
| P/E | 29.4 | 34.7 |
| P/B | 4.58 | — |
| Dividend yield | 0.97% | — |
| Profitability | ||
| Return on equity | 15.6% | — |
| Net profit margin | 14.3% | 23.1% |
| Operating margin | 20.1% | 28.1% |
| Growth | ||
| Revenue growth (YoY) | +10.9% | +4.3% |
| Net profit growth (YoY) | -21.7% | +17.1% |
| Revenue CAGR (multi-year) | +9.9% | — |
| Financial health | ||
| Debt to equity | 0.12 | — |
| Momentum | ||
| 1-month return | -1.0% | +1.0% |
| 1-year return | -4.3% | -11.3% |
| 3-year CAGR | +11.5% | +4.2% |
| 5-year CAGR | +8.0% | +5.6% |
| 10-year CAGR | +13.0% | +18.8% |
| Distance from 52W high | -10.1% | -12.8% |
| Technicals | ||
| RSI (14) | 71 | 52 |
| Price vs 200-day avg | -2.4% | -1.0% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Alkem Laboratories | Abbott India |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✗ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 6/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Alkem Laboratories or Abbott India?
Alkem Laboratories has a market cap of ₹63,326 Cr and Abbott India has a market cap of ₹55,983 Cr as of 06 Nov 2026.
Which has a lower P/E, Alkem Laboratories or Abbott India?
Alkem Laboratories has the lower P/E: Alkem Laboratories trades at 29.4 and Abbott India at 34.7.
Which gave better returns in the last year, Alkem Laboratories or Abbott India?
Alkem Laboratories did better: Alkem Laboratories returned -4.3% and Abbott India returned -11.3% over one year.
Is Alkem Laboratories or Abbott India a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Alkem Laboratories scores 6/10 and Abbott India scores 5/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.